Platinum-resistant ovarian high grade serous adenocarcinoma

Clinical trials for Platinum-resistant ovarian high grade serous adenocarcinoma explained in plain language.

Never miss a new study

Get alerted when new Platinum-resistant ovarian high grade serous adenocarcinoma trials appear

Sign up with your email to follow new studies for Platinum-resistant ovarian high grade serous adenocarcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

New drug cocktail targets Hard-to-Treat HER2 cancers

Disease control Recruiting now

This early-phase trial tests a combination of two drugs—DS-8201a and olaparib—in people with advanced HER2-expressing cancers that have spread or cannot be removed. DS-8201a delivers chemotherapy directly to HER2-positive tumor cells, while olaparib blocks DNA repair in cancer ce…

Matched conditions: PLATINUM-RESISTANT OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA

Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Sep 10, 2026 00:00 UTC

Platinum-resistant ovarian high grade serous adenocarcinoma

Get alerted when new Platinum-resistant ovarian high grade serous adenocarcinoma trials appear

New drug cocktail targets Hard-to-Treat HER2 cancers